Is RSPI or QYLD a better dividend investment in 2026?

RSPI currently yields 111111.11% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: RSPI offers higher current income.

What is the dividend yield difference between RSPI and QYLD?

RSPI has a forward dividend yield of 111111.11% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 111099.19 percentage points.

Home › Compare › RSPI vs QYLD

RSPI vs QYLD: Dividend Comparison 2026

RSPI yields 111111.11% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 RSPI wins by $1.3838190899465547e+27M in total portfolio value

INVESTMENT

TIME HORIZON10 years

RSPI

● Live price

111111.11%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$1.3838190899465547e+27M

Annual income

$1,381,373,456,343,941,000,000,000,000,000,000.00

Full RSPI calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — RSPI vs QYLD

📍 RSPI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	RSPI	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, RSPI + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

RSPI pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RSPI

Annual income on $10K today (after 15% tax)

$9,444,444.44/yr

After 10yr DRIP, annual income (after tax)

$1,174,167,437,892,349,800,000,000,000,000,000.00/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, RSPI beats the other by $1,174,167,437,892,349,800,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RSPI + QYLD for your $10,000?

RSPI: 50%QYLD: 50%

100% QYLD50/50100% RSPI

Portfolio after 10yr

$6.919095449732774e+26M

Annual income

$690,686,728,171,970,500,000,000,000,000,000.00/yr

Blended yield

99.82%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RSPI buys

QYLD buys

No recent congressional trades found for RSPI or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricRSPIQYLD

Forward yield	111111.11% ✓	11.92%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$1.3838190899465547e+27M	$25.4K ✓
Annual income after 10y	$1,381,373,456,343,941,000,000,000,000,000,000.00 ✓	$5,659.31
Total dividends collected	$1.383658847866035e+27M	$27.1K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: RSPI vs QYLD ($10,000, DRIP)

Year	RSPI Portfolio	RSPI Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$11,121,811	$11,111,111.11	$10,352	$1,192.36	+$11.11M → RSPI
2	$11,561,029,218	$11,549,128,879.66	$10,830	$1,347.57	+$11561.02M → RSPI
3	$11,232,204,364,934	$11,219,834,063,671.13	$11,460	$1,539.07	+$11232204.35M → RSPI
4	$10,199,601,320,781,262	$10,187,582,862,110,782.00	$12,275	$1,777.84	+$10199601320.77M → RSPI
5	$8,656,721,364,988,387,000	$8,645,807,791,575,153,000.00	$13,323	$2,078.95	+$8656721364988.37M → RSPI
6	$6,867,176,795,058,000,000,000	$6,857,914,103,197,462,000,000.00	$14,667	$2,463.34	+$6867176795058000.00M → RSPI
7	$5,091,669,942,459,710,000,000,000	$5,084,322,063,288,997,000,000,000.00	$16,396	$2,960.57	+$5091669942459709440.00M → RSPI
8	$3,528,599,356,203,225,300,000,000,000	$3,523,151,269,364,793,600,000,000,000.00	$18,631	$3,612.97	+$3.5285993562032256e+21M → RSPI
9	$2,285,638,880,947,370,600,000,000,000,000	$2,281,863,279,636,233,000,000,000,000,000.00	$21,548	$4,482.15	+$2.2856388809473705e+24M → RSPI
10	$1,383,819,089,946,554,900,000,000,000,000,000	$1,381,373,456,343,941,000,000,000,000,000,000.00	$25,398	$5,659.31	+$1.3838190899465547e+27M → RSPI

RSPI vs QYLD: Complete Analysis 2026

RSPI — Stock

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.

Full RSPI Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this RSPI vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RSPI vs SCHD RSPI vs JEPI RSPI vs O RSPI vs KO RSPI vs MAIN RSPI vs XYLD RSPI vs JEPQ RSPI vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.